Autolus Therapeutics plc (AUTL)

4,2500 +0,0600 (+1,43%) In data: 09:34AM EDT. Mercato aperto.

Autolus Therapeutics plc

The Mediaworks
191 Wood Lane White City
London W12 7FP
United Kingdom
44 20 3829 6230
https://www.autolus.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 463

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Christian Martin Itin Ph.D.	CEO & Director	2,41M	N/D	1964
Dr. Martin Pule M.D., MBBS	Founder, Senior VP & Chief Scientific Officer	N/D	N/D	1972
Mr. Robert F. Dolski	Senior VP & CFO	N/D	N/D	1971
Mr. Christopher Vann	Senior VP & COO	N/D	N/D	1965
Mr. David Brochu	Senior VP & Chief Technical Officer	N/D	N/D	1956
Mr. Alexander Swan	Senior VP & Chief Human Resources Officer	N/D	N/D	1965
Mr. Brent Rice	Senior VP, Chief Commercial Officer & Site Head of US	N/D	N/D	1966
Ms. Olivia Manser	Director of Investor Relations	N/D	N/D	N/D
Mr. Alex Driggs	Senior VP of Legal Affairs & General Counsel and Secretary	N/D	N/D	N/D
Dr. Chris Williams	Senior VP & Chief Business Development Officer	N/D	N/D	1980

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Autolus Therapeutics plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.